The Jasti Family Trust has sold 7.7 million shares of Cohance Lifesciences Ltd. in a bulk deal, with Jasub Property stepping in as the buyer. The transaction reshapes the company’s shareholder profile, signaling strategic portfolio adjustments and renewed investor interest in the pharmaceutical and life sciences sector.
In a significant market development, the Jasti Family Trust executed a bulk deal involving the sale of 7.7 million shares of Cohance Lifesciences Ltd.. The stake was acquired by Jasub Property, marking a notable reshuffle in the company’s ownership structure.
Cohance Lifesciences, a growing player in the pharmaceutical and life sciences industry, has been attracting investor attention due to its focus on specialty chemicals, APIs, and contract development services. The transaction highlights both the trust’s portfolio realignment and Jasub Property’s confidence in the company’s long-term growth potential.
Market analysts suggest that such bulk deals often indicate strategic capital reallocation, while also providing liquidity and signaling fresh investor interest. The move is expected to strengthen Cohance’s visibility in the capital markets.
Key Highlights
-
Seller: Jasti Family Trust.
-
Shares Sold: 7.7 million in bulk deal.
-
Buyer: Jasub Property acquires stake.
-
Sector: Pharmaceuticals and life sciences.
-
Strategic Impact: Portfolio reshuffle and renewed investor confidence.
This transaction underscores the dynamic nature of India’s pharma investment landscape, where institutional and private investors continue to seek opportunities in high-growth segments.
Sources: Business Standard Markets; Economic Times Corporate Announcements; Moneycontrol Bulk Deals Report